Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021

Ocugen Inc.宣布取消先前休会至美国东部时间2021年1月13号上午11:00的股东大会

2021-01-14 05:01:52 BioSpace


MALVERN, Pa., Jan. 12, 2021 -- Ocugen, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced it has determined to withdraw from stockholder consideration Item 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on October 30, 2020, with respect to an increase in the number of shares of common stock authorized for issuance under the Company’s Sixth Amended and Restated Certificate of Incorporation. As a result, the Company has determined to cancel the reconvening of its annual meeting of stockholders, which was previously adjourned solely with respect to Item 2 to 11:00 a.m. Eastern Time on January 13, 2021. All other items set forth in the Company’s Definitive Proxy Statement were submitted to stockholder vote at the Company’s annual meeting of stockholders on December 23, 2020. The Company plans to re-evaluate the details of Item 2 in light of the recent potential addition of COVAXIN™ to its pipeline as well as its compliance with Nasdaq’s Listing Rule 5550. About Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com. Cautionary Note on Forward-LookingStatements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Corporate Contact: Ocugen, Inc. Sanjay Subramanian Chief Financial Officer IR@Ocugen.com Media Contact: LaVoieHealthScience Emmie Twombly etwombly@lavoiehealthscience.com +1 857-389-6042
马尔文,宾夕法尼亚州,2021年1月12日--生物制药公司Ocugen,Inc.,一家专注于发现,开发和商业化治疗失明疾病的基因疗法和开发抗击COVID-19的疫苗的生物制药公司,今天宣布它已决定退出其于2020年10月30日提交给证券交易委员会的最终代理声明中所列的股东对价项目2,该项目涉及根据公司第六次修订和重述的公司注册证书授权发行的普通股股票数量的增加。因此,本公司已决定取消重新召开股东年会,此前仅就项目2休会至美国东部时间2021年1月13日上午11:00。本公司最终委托书所载所有其他项目已于二零一二年十二月二十三日于本公司股东周年大会上提交股东表决。鉴于Covaxin™最近可能加入其管道,以及其符合纳斯达克上市规则5550,该公司计划重新评估第2项的细节。 关于Ocugen公司。 Ocugen公司是一家生物制药公司,致力于发现,开发和商业化治疗失明疾病的基因疗法,并开发抗击Covid-19的疫苗。我们突破性的修饰基因治疗平台具有用一种药物治疗多种视网膜疾病的潜力,我们新的生物候选产品旨在为治疗不足的疾病如湿性年龄相关性黄斑变性,糖尿病性黄斑水肿和糖尿病性视网膜病变的患者提供更好的治疗。欲了解更多信息,请访问www.ocugen.com。 关于前瞻性陈述的警告性说明 本新闻稿包含1995年《私人证券诉讼改革法》含义范围内的前瞻性陈述,这些陈述受到风险和不确定性的影响。在某些情况下,我们可能会使用诸如预测,相信,潜在,预计,继续,估计,预期,预期,计划,打算,可能,可能,可能,可能,will,should或其他表达未来事件或结果不确定性的词语来识别这些前瞻性陈述。这种陈述受到许多重要因素,风险和不确定因素的影响,这些因素,风险和不确定因素可能导致实际事件或结果与我们目前的预期大相径庭。我们在向证券交易委员会(SEC)提交的定期报告中更全面地描述了这些和其他风险和不确定性,包括我们向SEC提交的季度和年度报告中题为“风险因素”的章节中描述的风险因素。我们在本新闻稿中所作的任何前瞻性陈述仅限于本新闻稿发布之日。除法律要求外,我们不承担更新本新闻稿中包含的前瞻性陈述的义务,无论是由于新信息,未来事件或其他原因,在本新闻稿发布日期之后。 公司联系人: Ocugen公司。 桑贾伊·苏布拉马尼安 首席财务官 IR@ocugen.com 媒体联系人: 拉沃耶卫生科学 埃米·托姆布莱 电子邮件:etwombly@lavoiehealthscience.com +1 857-389-6042